Remimazolam for Emergence Delirium Prevention in Patients Undergoing Rhinoseptoplasty, FESS or Septoplasty

Launched by UNIVERSITY HOSPITAL OF SPLIT · May 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called remimazolam to see if it can help prevent a condition known as emergence delirium, which is confusion and agitation that some patients experience when waking up from anesthesia. The trial involves adult patients aged 18 to 65 who are scheduled for specific nose surgeries, including rhinoplasty, rhinoseptoplasty, or functional endoscopic sinus surgery (FESS). Participants will be divided into two groups: one will receive remimazolam before their surgery, while the other will receive a placebo (a harmless saline solution).

To participate, patients should be generally healthy (classified as ASA I or II) and not pregnant. They also should not have been on psychiatric medications in the six months leading up to the surgery. Throughout the trial, researchers will closely monitor patients for signs of delirium during recovery, as well as their pain levels, recovery room stay duration, any unwanted side effects, and mood changes after surgery. This study aims to ensure a smoother recovery process for patients undergoing these types of surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients scheduled for rhinoplasty, rhinoseptoplasty or FESS
• • ASA I or II
• Exclusion Criteria:
• • pregnancy
• • patients treated with psychiatric medication (in the time of operation or 6 months prior to operation)